Dermatologic toxicities of antibody- drug conjugates

被引：2

作者：

Gronbeck, Christian

Hadfield, Matthew J.

Grant-Kels, Jane M. ^{[1
,2
]}

机构：

[1] Univ Connecticut, Hlth Ctr, Dept Dermatol, 21 South Rd,2nd Floor, Farmington, CT 06032 USA

[2] Univ Florida, Coll Med, Dept Dermatol, Gainesville, FL USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 06期

关键词：

adverse events; antibody-drug conjugates; cutaneous toxicity; dermatologic toxicity; mono-clonal antibodies; oncology; skin; ACUTE MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; NON-HODGKIN-LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; OPEN-LABEL; TRASTUZUMAB EMTANSINE; INOTUZUMAB OZOGAMICIN; POLATUZUMAB VEDOTIN;

D O I：

10.1016/j.jaad.2024.08.036

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Antibody-drug conjugates (ADCs) are a new and emerging category of oncologic treatments that combine the target specificity of a monoclonal antibody with a cytotoxic payload. These drugs are associated with unique cutaneous toxicities that vary across agents. Currently, there are eleven ADCs with regulatory approval for solid and liquid tumors and over 80 ADCs currently in clinical development, it is critical for dermatologists to recognize and appropriately mitigate the cutaneous toxicities associated with these therapies. This clinical review will summarize the novel mechanisms and indications of approved ADCs, discuss dermatologic toxicities demonstrated in clinical trials and postmarketing studies, and impart recognition and management guidance when encountering these reactions to help maintain patients safely and comfortably on their medications. ( J Am Acad Dermatol 2024;91:1177-88.)

引用

页码：1177 / 1188

页数：12

共 126 条

[1] Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data [J].

Agostinelli, Veronica ;

Musacchio, Lucia ;

Camarda, Floriana ;

Salutari, Vanda ;

Carbone, Maria Vittoria ;

Ghizzoni, Viola ;

Nero, Camilla ;

Ricci, Caterina ;

Perri, Maria Teresa ;

Giudice, Elena ;

Lardino, Sara ;

Berardi, Rossana ;

Scambia, Giovanni ;

Lorusso, Domenica .

CANCER MANAGEMENT AND RESEARCH, 2023, 15 :1063-1072

[2] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Aversa, Franco ;

Gaidano, Gianluca ;

Musso, Maurizio ;

Annino, Luciana ;

Venditti, Adriano ;

Voso, Maria Teresa ;

Mazzone, Carla ;

Magro, Domenico ;

De Fabritiis, Paolo ;

Muus, Petra ;

Alimena, Giuliana ;

Mancini, Marco ;

Hagemeijer, Anne ;

Paoloni, Francesca ;

Vignetti, Marco ;

Fazi, Paola ;

Meert, Liv ;

Ramadan, Safaa Mahmoud ;

Willemze, Roel ;

de Witte, Theo ;

Baron, Frederic .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+

[3] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial [J].

Andre, Fabrice ;

Park, Yeon Hee ;

Kim, Sung-Bae ;

Takano, Toshimi ;

Im, Seock-Ah ;

Borges, Giuliano ;

Lima, Joao Paulo ;

Aksoy, Sercan ;

Gavila Gregori, Joaquin ;

De Laurentiis, Michelino ;

Bianchini, Giampaolo ;

Roylance, Rebecca ;

Miyoshi, Yasuo ;

Armstrong, Anne ;

Sinha, Rajni ;

Ruiz Borrego, Manuel ;

Lim, Elgene ;

Ettl, Johannes ;

Yerushalmi, Rinat ;

Zagouri, Flora ;

Duhoux, Francois P. ;

Fehm, Tanja ;

Gambhire, Dhiraj ;

Cathcart, Jillian ;

Wu, Cai ;

Chu, Changan ;

Egorov, Anton ;

Krop, Ian .

LANCET, 2023, 401 (10390) :1773-1785

[4]

[Anonymous], Common Terminology Criteria for Adverse Events (CTCAE)

[5]

[Anonymous], 2022, ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use

[6] Antibody-Drug Conjugates-A Tutorial Review [J].

Baah, Stephanie ;

Laws, Mark ;

Rahman, Khondaker Miraz .

MOLECULES, 2021, 26 (10)

[7] Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin [J].

Badar, Talha ;

Szabo, Aniko ;

Wadleigh, Martha ;

Liedtke, Michaela ;

Arslan, Shukaib ;

Siebenaller, Caitlin ;

Aldoss, Ibrahim ;

Schultz, Elizabeth ;

Hefazi, Mehrdad ;

Litzow, Mark R. ;

Kuo, Eric ;

Wang, Amy ;

Curran, Emily ;

Shallis, Rory M. ;

Podoltsev, Nikolai ;

Balasubramanian, Suresh ;

Yang, Jay ;

Mattison, Ryan ;

Burkart, Madelyn ;

Dinner, Shira ;

Advani, Anjali ;

Atallah, Ehab .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (08) :556-+

[8] Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database [J].

Barbieri, Maria Antonietta ;

Sorbara, Emanuela Elisa ;

Cicala, Giuseppe ;

Santoro, Vincenza ;

Cutroneo, Paola Maria ;

Franchina, Tindara ;

Spina, Edoardo .

DRUGS-REAL WORLD OUTCOMES, 2022, 9 (01) :91-107

[9] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[10] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Mayer, I. A. ;

Vahdat, L. T. ;

Tolaney, S. M. ;

Isakoff, S. J. ;

Diamond, J. R. ;

O'Shaughnessy, J. ;

Moroose, R. L. ;

Santin, A. D. ;

Abramson, V. G. ;

Shah, N. C. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Sweidan, A. M. ;

Iannone, R. ;

Washkowitz, S. ;

Sharkey, R. M. ;

Wegener, W. A. ;

Kalinsky, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751

← 1 2 3 4 5 6 7 8 9 10 →